Attached files
| file | filename |
|---|---|
| EX-31.2 - EX-31.2 - TEVA PHARMACEUTICAL INDUSTRIES LTD | d26234dex312.htm |
| EX-31.1 - EX-31.1 - TEVA PHARMACEUTICAL INDUSTRIES LTD | d26234dex311.htm |
| 10-Q - 10-Q - TEVA PHARMACEUTICAL INDUSTRIES LTD | d26234d10q.htm |
Exhibit 32
CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Teva Pharmaceutical Industries Limited (the “Company”) on Form 10-Q for the period ended March 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), we, Kåre Schultz, President and Chief Executive Officer of the Company, and Eli Kalif, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that:
| (1) | The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
| (2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
Dated: April 28, 2021
| /s/ Kåre Schultz |
| Kåre Schultz |
| President and Chief Executive Officer |
| /s/ Eli Kalif |
| Eli Kalif |
| Executive Vice President, Chief Financial Officer |